Chinese Scientists Engineer Ebola-Based Virus, Raising Concerns Over Potential Lethality

Scientists at China’s Hebei Medical University have engineered a virus using components of the Ebola virus, aiming to study the disease and its symptoms. However, this development has raised concerns due to the pathogen’s potential lethality, reportedly killing lab hamsters within three days.

This new virus variant has emerged amid ongoing conspiracy theories suggesting that COVID-19, which caused millions of deaths, originated from a lab leak in Wuhan.

The study, published in Science Direct, details how researchers utilized a glycoprotein from the Ebola virus, which allows the virus to infect cells and spread throughout the human body.

The engineered strain induced severe systemic illnesses similar to human Ebola patients, including multi-organ failure.

The study observed that some hamsters developed scabs on their eyeballs, impairing their vision. According to the researchers, “It is a sign that 3-week-old Syrian hamsters infected with the virus could play a role in studying optic nerve disorders caused by Ebola virus disease (EVD).”

Animal experiments were conducted following approval from the animal experimental committee of the Laboratory Animal Center, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Science.

Since COVID-19 was declared a public health emergency in January 2020, debates over its origin have persisted, with some attributing its spread to a live animal market and others to a lab leak. In this study, the Chinese researchers emphasized their goal was to replicate Ebola symptoms in a controlled environment to facilitate prevention strategies.

Notably, the scientists used vesicular stomatitis virus (VSV) to transport the Ebola glycoprotein, as handling the deadly Ebola virus requires highly secure Biosafety Level 4 (BSL-4) facilities. The glycoprotein is crucial for the virus’s ability to infect host cells.

The researchers noted, “Overall, this surrogate model represents a safe, effective, and economical tool for rapid preclinical evaluation of medical countermeasures against the Ebola virus under BSL-2 conditions, which would accelerate technological advances and breakthroughs in combating Ebola virus disease.”

You cannot copy content of this page